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Ethnopharmacological  relevance:  GP-TCM  is  the  ﬁrst  EU-funded  Coordination  Action  consortium  dedicated
to traditional  Chinese  medicine  (TCM)  research.  One  of  the  key  deliverables  of  the  Work  Package  7 in  GP-
TCM was  to  investigate  information  of the  existing  requirements  for  registration  of  TCM  products  listed
by  global  regulatory  bodies.  The  paper  aims  to collate  data  and  draw  comparison  of these  regulations.  Case
studies  are  also  presented  to illustrate  the  problems  involved  in  registering  TCM  products  in  different
regions  worldwide.
Materials  and  methods:  A collaborative  network  task  force was  established  during  the  early  stage  of  the
GP-TCM  project  and  operated  through  exchanges,  teleconferences  and  focused  discussions  at  annualomparison of regulatory requirements for meetings.  The  task  force  involved  coordinators,  academics  who  are  actively  involved  with  R&D  of  Chi-
nese herbal  medicines,  experts  on  monographic  standards  of  Chinese  materia  medica,  representativesegistration
from  regulatory  agencies,  experts  from  industries  in  marketing  Chinese  medicines/herbal  medicines  and
natural products.  The  co-ordinators  took  turns  to  chair  teleconferences,  led  discussions  on  speciﬁc  issues
at AGM  discussion  sessions,  at joint  workshops  with  other  work-packages  such  as  WP1  (quality  issues),
WP3  (toxicology  issues)  and WP6  (clinical  trial issues).  Collectively  the  authors  were  responsible  for
collating  discussion  outcomes  and  updating  written  information.
Abbreviations: CHM, Chinese herbal medicine; CMM,  Chinese materia medica or Chinese medicinal material; CHP, complex herbal products; EDQM,
uropean Directorate for Quality Medicines & Healthcare; EMA, European Medicines Agency; EU, European Union; FDA, Food and Drug Administration (USA); FP7,
th  Framework Programme; GP-TCM, Good Practice in Traditional Chinese Medicine Research in the Post-genomic Era; GxP, good practice guidelines; MHRA, Medicines
nd  Healthcare products Regulatory Agency (UK); R&D, Research and development; SFDA, State Food and Drug Administration (P.R. China); TCM, Traditional Chinese
edicine; TGA, Therapeutic Goods Administration (Australia); THMP, traditional herbal medicinal product; WP,  work package.
∗ Corresponding author at: Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge CB2 1PD, UK. Tel.: +44 1223 334015/334025;
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uccessful registration of herbals, their particular route to market and lessons learnt to date.
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Results:  A  global  overview  of  regulations  on  herbal  registration  has  been  compiled  during  the  three  years
of  the  consortium.  The  regulatory  requirements  for  registration  of  herbal  products  in  the  EU  and  China
were  compared,  and  this  is  extended  to other  regions/countries:  Africa,  Australia,  Brazil,  Canada,  Japan,
Russia,  South  Korea,  Taiwan,  and  the  United  States.  A wide  variation  of  the regulations  for  the  categories
of  herbal  products  exists:  food  (functional  food,  novel  foods,  dietary  food  for  special  medical  purpose,
foods  for  particular  nutritional  use,  food  supplement);  cosmetic,  traditional  herbal  medicine  products;
herbal  medicines  for  human  use  and  veterinary  use.
Conclusion:  The  regulatory  issues  for registration  of  herbal  products  are  complicated  among  the countries
and  regions  worldwide.  The  information  summarised  in  the  text  is  for  reference  only.  Some  regulations
which  are  presented  in  this  review  are  still  in  legislation  process  and  may  change  in  due  course.  Before
taking  any  regulatory  action,  readers  are  advised  to  consult  current  ofﬁcial  legislation  and guidance  and/or
to  seek  appropriate  professional  advice.  The  lessons  learnt  from  global  regulation  of TCM will provide
valuable  insights  for regulation  of  other  traditional  medicine  such  as Ayurveda  and  Unani  medicine,  as
well  as  other  forms  of indigenous  medicine.  The  WHO  is well  placed  to co-ordinate  a  consultation  process
with  the  aim  of  putting  forward  suggestions  for  harmonisation  to key  regulatory  agencies.
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f. The task of Work Package 7 within the GP-TCM
onsortium
In 2005, the WHO  global survey on National Policy on Tradi-
ional Medicine and Regulation of Herbal Medicines pointed out
hat there has been increasing use of complementary and alterna-
ive medicines (CAM) in many developed and developing countries.
he safety and efﬁcacy of traditional medicine and complementary
nd alternative medicines, as well as quality control, have become
mportant concerns for both Health Authorities and the public.
GP-TCM (Good Practice in Traditional Chinese Medicine
esearch in the Post-genomic Era) is the ﬁrst EU-funded Coordina-
ion Action consortium dedicated to traditional Chinese medicine
TCM) research. The Work Package 7 of GP-TCM was assigned the
ask to collate accurate and reliable information on the regulatory
equirements for registration of TCM products in the EU.
At an early stage in the project, it became very clear that strin-
ent government regulation is crucially important to ensure the
uality, efﬁcacy and safety of herbal products and ideally standards
hould be harmonised at international level. Therefore, one of the
ims of GP-TCM Work Package 7 (WP7) is to establish a collabo-
ative network towards formulating an easy-to-follow statement
n the various regulatory frameworks for herbals, emphasising the
ynergies and highlighting the differences, in order to contribute to
he long term goal of global harmonisation.
In line with GP-TCM’s overall objective, the authors of this arti-
le have investigated and compared the applicable regulations of
urope and China. To encompass WP7’s global outlook, the authors
ave also considered the regulations and laws of other countries
nd regions (in alphabetical order): Africa, Australia, Brazil, Canada,
apan, Russia, South Korea, Taiwan and the United States. These
ountry-speciﬁc reviews are summarised and compared.
Various traditional medicine practices have been developed in
ifferent cultures in different regions, but without a parallel devel-
pment of international standards and appropriate methods for
valuating traditional medicine. Therefore, sharing national expe-
ience and information is crucial. We  believe that the lessons learnt
rom global regulation of TCM will provide valuable insights for reg-
lation of other traditional medicine such as Ayurveda and Unani
edicine, as well as other forms of indigenous medicine.
. Overview of herbal regulations worldwide
.1. EuropeWith the European Directive 2004/24/EC taking full effect on
0th April 2011, it is now illegal for companies to sell manu-
actured unlicensed herbal medicines within Europe without the© 2012 Elsevier Ireland Ltd. 
appropriate license i.e. a Marketing Authorization (MA) or a Tra-
ditional Herbal Registration (THR). The UK differs slightly from
the rest of Europe in that herbal practitioners are to be regulated
as from April 2012 allowing for unlicensed manufactured herbal
medicines to be prescribed following a face-to-face consultation.
2.1.1. Overview
The main regulatory body is the European Medicines Agency
(EMA) but each Member State also has their own  regulatory agency
e.g. The Medicines and Healthcare products Regulatory Agency
(MHRA) in the UK, and The Federal Institute for Drugs and Medi-
cal Devices (Bundesinstitut für Arzneimittel und Medizinprodukte,
BfArM) in Germany. To date, there is no separate regulation for the
registration of TCMs. Instead, there are several different routes to
market for herbal products within Europe:
• food (functional food, novel foods, dietary food for special medi-
cal purpose, foods for particular nutritional use – PARNUTS, food
supplement),
• cosmetic,
• traditional herbal medicinal product (THMP),
• medicine for human use (Well Established Use, full Marketing
Authorization), or
• veterinary product.
It is important, therefore, to determine the classiﬁcation of the
herbal product. This may  seem to be stating the obvious but many
companies and researchers assume that if their product contains
herbal actives, automatically it must be registered as a THMP but
this is not always the case. The classiﬁcation of herbal products can
often be determined by the overall strategy of the company pro-
ducing the remedy. For example, classiﬁcation as a medical device
(e.g. ear drops, skin patches) may  be possible and more desirable:
registration is generally quicker and therefore a company’s invest-
ment will reach breakeven much sooner than via the ‘traditional’
route. For the purpose of this article, however, the authors have
chosen to focus on the Traditional Herbal Registration Scheme as
this has had the greatest impact on the European herbal industry
in recent times.
2.1.2. Why  did the EU want to regulate herbal remedies?
Increasingly consumers have turned to plant-derived remedies
in the belief that these ‘natural’ products are ‘safer’ than conven-
tional medicines. The words “natural”, “herbal” and “plant-derived”
Open access under CC BY-NC-ND license.can be misleading and it is important for the public to be reminded
that herbal remedies are medicines in their own right. Health
Authorities have been concerned about the safety proﬁle and qual-
ity of such medicines for a number of years now. For example,
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t is well known that St. John’s Wort interacts with SSRIs and
ral contraceptives. In some national markets, such as Germany,
rance and Austria, herbal preparations were already well deﬁned
nder existing laws. However, laws in other markets, such as The
etherlands and the UK were less stringent or, at the very least, less
ell enforced. So the EU Directive 2004/24/EC was implemented in
rder to harmonise the regulations, enable the free movement of
erbal products within Europe and protect the consumer.
.1.3. Traditional Herbal Registration Scheme
In March 2004 the European Directive 2004/24/EC was  adopted
nd so the term “traditional herbal medicinal product” (THMP) was
stablished.
The word “traditional” is key: it is important to demonstrate that
he herbal medicine or ‘corresponding’ (i.e. comparable) product(s)
as been in traditional medicinal use for 30 years preceding the date
f the application for the required medicinal indication. 15 years of
his usage must have been within the European Union (EU). The
atter is not absolutely essential and therefore, if the 15 years of
sage in the EU cannot be satisﬁed but the product(s) meets all
he other requirements of the Directive, the Health Authority can
efer the product(s) to the Committee on Herbal Medicinal Products
HMPC) who have the discretion to lower the requirement for 15
ears’ use (but there is no guarantee of this).
.1.4. Key requirements of the Traditional Herbal Medicinal
roducts Scheme (THMPS)
The THMP dossier must follow the Common Technical Docu-
ent (CTD) format (Fig. 1). The CTD is designed for use in Europe,
apan and America and consists of 5 Modules:
Module 1: Administrative and prescribing information.
Module 2: Overview and summary of modules 3–5.
Module 3: Quality (pharmaceutical documentation).
Module 4: Safety (toxicology studies).
Module 5: Efﬁcacy (clinical studies).
This format has also been adopted by several other countries
ncluding Canada and Switzerland. The THMPS, however, follows a
impliﬁed version of the usual CTD format (see below).
.1.4.1. Safety. This is where the ‘simpliﬁcation’ of the registra-
ion requirements for a traditional herbal remedy can clearly be
een as compared to a conventional pharmaceutical medicine. In
his instance Module 4 of the Common Technical Document (CTD)
equires bibliographical evidence on safety (including cross refer-
ncing to the appropriate Expert Report) and therefore replaces
he usual non-clinical study reports. If, however, the herbal sub-
tance is included on the Community List (European Medicines
gency, 2011), the need to provide a safety summary to support
he application is removed.
If a safety summary is required it must consider:
all herbal ingredients (+ vitamins or minerals),
use in pregnancy, lactation etc.,
potential interactions with other medication, herbal products
and/or food.
.1.4.2. Conﬁrm ‘traditional use’ of the product. As with ‘safety’
utlined in point (i) above, this is a key part of the CTD for tra-
itional herbal medicines and consists of bibliographical evidence.
t replaces the usual requirement of clinical studies in Module 5
lthough if studies are available these should be included.
So what is meant by “traditional”? Put simplistically, it is an
erbal product which:macology 140 (2012) 568– 586
• is intended and designed for use without the intervention of a
medical practitioner for diagnosis, prescription or monitoring of
treatment;
• is taken orally, for external use or inhalation;
• the efﬁcacy must be ‘plausible on the basis of long-standing use
and experience’.
Acceptable sources of evidence include:
• information from handbooks of medicine, pharmacy, pharmacol-
ogy, phytotherapy, herbal medicine, pharmacopoeia;
• ofﬁcial expert committee reports, ESCOP monographs;
• product related documentation (e.g. product brochures); and
• company archive materials (e.g. sales invoices).
2.1.4.3. Quality. Even if the herbal substance is included on the
Community List (European Medicines Agency, 2011), quality must
still be demonstrated. Quality applies from the Field to Finished
Product. Good Agricultural and Collection Practice (GACP) and Good
Manufacturing Practice (GMP) are examples of some of the required
practices and systems which need to be followed. Herbal prod-
ucts must contain the correct ingredients of acceptable quality,
free from unacceptable contamination; and the claimed shelf life of
the product must be supported. The normal quality requirements
applicable to licensed medicines apply. There is also a requirement
to hold a manufacturer’s license, a wholesale dealer’s license or a
wholesale dealer’s (import) license where appropriate.
As a result of several discussions with those companies operat-
ing in the herbal industry as well as with agency representatives,
quality appears to be the most challenging aspect of registration
with examples of products from India and China using different
genera for different batches of the same herbal remedy.
2.1.4.4. Labels and leaﬂets – readability/user testing (Directive
2001/83/EC).
“The package leaﬂet shall reﬂect the results of consultations with
target patient groups to ensure that it is legible, clear and easy to
use” (European Parliament, 2001b)
The aim of a readability test is to demonstrate that patients can:
• locate information in the PIL,
• understand it, and
• know how to act on it.
The product labelling and leaﬂet must include the statement:
“product X is a traditional herbal medicinal product for use in spec-
iﬁed indications exclusively based on longstanding use”
And the correct certiﬁcation registration mark must be used:
http://www.mhra.gov.uk/Howweregulate/Medicines/Herbal
medicines/PlacingaherbalmedicineontheUKmarket/Traditional
HerbalMedicinesRegistrationScheme/TraditionalHerbal
Registrationcertiﬁcationmark/index.htm.
2.1.4.5. Advertising. Speciﬁc advertising requirements (European
Parliament, 2007) apply to THMPs over and above other provi-
sions and speciﬁc extra wording on advertisements of THMPs are
required:
“Traditional herbal medicinal product for use in (registered indi-
cation) exclusively based upon long-standing use as a traditional
remedy”
It is important to remember that THMPs are registered for
“use in minor self-limiting conditions that are suitable for self-
management and do not require the intervention of a medical
opharm
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ractitioner.” (Medicines and Healthcare products Regulatory
gency, 2011)
.1.4.6. Article 16d (European Parliament, 2001a, 2004). It is possible
o obtain mutual recognition of the registration of a THMP in the EU.
ut simply, this is the process by which EU countries may  approve
he decision made about a THMP by another EU country. A company
ubmits their application to the country chosen to carry out the
ssessment work which then approves or rejects the application.
he other countries then have 90 days to decide to approve the
ecision made by the original country.
Article 16d of Directive 2004/24/EC (as amended) outlines that:
mutual recognition shall apply to registration if covered by a
Community Herbal Monograph;
the herbal ingredient is recorded on the Community List; and
Member States must take into account registration by other
Member States.
So far THMP registrations have only been at national level and as
et, companies have not taken advantage of the Mutual Recognition
rocedure (MRP).
.1.4.7. Enforcement. The herbal industry is being actively policed
ot only by the regulatory agencies themselves but also by the com-
etitors and members of the public and it tends to be non-compliant
ebsites and promotional activities which bring companies to the
ttention of the authorities.
.1.5. Case study: UK based Chinese company
Early in April 2011, a regulatory consultancy was  approached by
 Chinese company trading in the UK. The company produces herbal
ranules and ﬁnished product. They were aware of the THMPD
nd the imminent deadline of 30 April 2011. Unfortunately, they
ere naïve and thought that as long as they reached compliance at
ome point in the future, they could continue trading as they were.
n addition, the company’s employees were confused about the
HMPD requirements some of which was due to language and cul-
ural barriers. Some of the confusion arose, however, because they
ere selling granules as well as ﬁnished product but, depending on
ircumstances, granules can also be deemed to be “ﬁnished prod-
ct”. Further confusion arose because the company had products
n the US market and, as a result they had assumed that because
hey were compliant in the US this ‘compliance’ would translate
nto Europe. Unfortunately, this assumption was incorrect.
A meeting was held between the company and the consultancy
uring which it became clear little was in place to ensure com-
liance with THMPD. In May  2011, the company then received an
nannounced visit from the UK’s MHRA as a result of Customs and
xcise detaining a consignment of what was suspected to be unli-
ensed medicine entering the UK. At the time of writing this article,
his incident remains under investigation and a formal response
rom the MHRA is awaited.
With the approval of the MHRA, the company continues to
rovide herbal granules as ingredients to practitioners but all of
heir ﬁnished products have been returned to the manufacturers in
hina. It has been agreed that they will reassess their business when
hey have received a formal response from the MHRA and once the
egulation of herbal practitioners has been implemented. In prepa-
ation for this time (and after receiving further advice) they are in
iscussion with other similar companies with the aim of forming a
o-operative to share the costs for quality and pharmacovigilance
ctivities.acology 140 (2012) 568– 586 571
This is a particularly serious case as it involves criminal pro-
ceedings. The outcome will be a ﬁne of several thousand pounds
and may  also result in imprisonment of the company directors.
2.1.5.1. Case studies using Dantonic® (for human angina) and
Phytopica® (for canine skin health).
2.1.5.1.1. Case study 1 – Dantonic® (Danshen Diwan) for angina
produced by Tasly Pharmaceuticals, Co. Ltd., P.R. China. Although
Dantonic® is not a traditional herbal remedy, the authors believe
that the product proves to be a useful case study because it demon-
strates the complexity (and differences) of the various regulatory
pathways worldwide and, in particular, between China and Europe.
In turn, this highlights the difﬁculties facing companies trying to
develop plant based medicines whether novel or based on tradi-
tional formulae.
Dantonic® was developed as a novel formulation by pharma-
cists at a military hospital in Tianjin, China, in the early 1990s. The
ingredients were chosen based on TCM theory and accumulated
clinical experience for treating chronic stable angina pectoris due
to coronary artery disease. It contains 2 herbal extracts: Salvia mil-
tiorrhiza and Panax notoginseng) plus Borneolum syntheticum. It is
marketed (and prescribed by clinicians) in China but the 2 herbs
are also known to be used as food ingredients. Interestingly the
product has been legally marketed as a food/dietary supplement in
The Netherlands for many years (there is documentation conﬁrm-
ing that it is imported with approval from the Dutch authorities).
The Swedish Medical Products Agency (MPA), however, informed
the manufacturer that in their view Dantonic® is classiﬁed as a
medicine for the following reasons:
• they could not ﬁnd that the ingredients had been used in food
within the EU;
• they found many studies showing the ingredients have pharma-
cological properties, and
• the monograph in the Chinese Pharmacopoeia showed it is a
product intended for medicinal use.
In this instance, the medicinal use established in China was
enough to classify Dantonic® as a medicinal product and the option
of classiﬁcation as a food supplement was not possible in the EU.
This example shows an obstacle and challenge for CHMs enter-
ing the EU market i.e. the product will be classiﬁed as a medicine
because of the documented medicinal use in China. At the same
time the product does not qualify for the ‘simpliﬁed’ registration
path (Traditional Herbal Medicinal Product Registration) as docu-
mented use is not within the EU.
It is interesting that EU Agencies will recognise medicinal use
in China in one context but not in another. Since the ﬁrst launch
of Dantonic® in Vietnam in 1996, it has been legally marketed in
more than 26 countries or regions including Russia, South Korea,
Mongolia, Singapore, Vietnam, and South Africa as a prescription
drug or over-the-counter (OTC), in 32 counties include the United
States as dietary supplements, and in Canada as traditional drug
labeled with cardiovascular treatment indications. See Table 1 for
country-speciﬁc approval/initial launch status (correct as of May
2010).
2.1.5.1.2. Conclusion. Table 1 clearly demonstrates the signiﬁ-
cant variances in the classiﬁcation of the same herb-based product
showing the full spectrum from dietary supplement, OTC drug,
traditional drug, to prescription drug. It is well known that many
herbal ingredients in China, Korea, etc. are classiﬁed as “drug and
food from the same origin i.e. they can be used as ingredients for
food, soft drink, dietary supplement, and medical purpose depend
on method of use and normal daily intake amount. How such prod-
ucts are recognised by the different regulatory agencies is the key
to their future health beneﬁts to patients and commercial value
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The Provision for Drug Registration (SFDA order 28) provides
practical guidelines for the registration of drugs (State Food and
Drug Administration P.R. China, 2007). Drugs will be assessed for72 T.-P. Fan et al. / Journal of Ethn
o the manufacturer. It seems the method of use and daily intake
mount are not considered in the some countries but does in others
n classiﬁcation. Before any consideration can be made for the har-
onisation of regulations perhaps ﬁrst an agreement needs to be
eached in the future on the deﬁnition, and therefore classiﬁcation,
f these products.
.1.5.2. Case study 2 – Phytopica® for canine skin health developed
y Phytopharm and initially under licence to Intervet/Schering Plough,
K. Phytopica® is based on a traditional formula and, although it
as planned to obtain European registration for human use, it even-
ually gained successful registration as a veterinary foodstuff with
health claims’ (pre Article 13.5 but originally developed under the
rinciples of this Article). It is important to note that it cannot be
sed off-label for human patients.
The original 10 plant extract (Zemaphyte®) was developed for
uman use and progressed into phase III clinical trials. Registra-
ion was abandoned as it was too expensive to manufacture to
MP  standards (and also required further work). Additional clin-
cal trials of Phytopica® would need to be performed in humans
some had been performed but more would be needed). The origi-
al Phytopica® data package is identical to that of a human data
ackage and fully supports human clinical trials. In the end, 3
lant extracts (Rehmannia, Paeonia, Glycyrrhiza) were selected from
he original 10 plant extracts based on their pharmacology and
sage.
The clinical trials and manufacturing data package were
eviewed by the Veterinary Medicines Directorate (the veterinary
quivalent of the MHRA), and therefore were to ‘investigational
edicinal product standards’ both in the UK and France. Phytopica®
as launched as a veterinary foodstuff with ‘health claims’ for
he European market because it was a quicker route to market
nd therefore, could provide an immediate return on investment.
hese funds were then used to research and develop other potential
edicines.
Later, the product was licensed to Intervet/Schering Plough who
arketed and sold it in Europe and Asia. It proved difﬁcult to sell in
he US due to differing state laws which is why the company only
arketed Phytopica® in Europe and not the US.
The manufacturing methods used for Phytopica®, along with
he 3-plant extract combination, resulted in a novel product (hence
he product was able to be patented) which had not been used as
 medicine in China or Europe. As it had no previous history as a
edicine, this may  well have contributed to the company’s success
n launching the product as a veterinary foodstuff.
2.1.5.2.1. Conclusions. This case study demonstrates that
eveloping plant extracts for use as a food but which are tradition-
lly used as CHMs can be difﬁcult but not impossible particularly if
he plant extracts used are in a different combination. It is under-
tood that if, traditionally, the combination of plant extracts has
een used as a medicine in China then it will be classed as a
edicine in Europe. If separately the plant extracts are used as a
ood then it is likely that the product could be developed as food
i.e. a novel food and as a food with health claims (or possibly as a
edical food)).
.1.6. Summary
General consensus is that whether a product is a TCM, Ayurvedic
r Western herbal, the basic rules are the same i.e. the product will
eed a suitable product licence or Traditional Herbal Registration.
aterials of animal origin and chemical compounds are excluded.t is recognised that there are particular issues with, for example,
CMs in that proving a minimum of 15 years’ traditional use in
urope can be problematical. Interestingly, agencies perceive other
actors to be greater ‘stumbling blocks’. For example:macology 140 (2012) 568– 586
• quality often is not to required standards i.e. Good Agricultural
and Collection Practice (GACP), Good Manufacturing Practice
(GMP);
• some TCMs contain much more potent ingredients than is per-
mitted under the THMRS; and
• some TCMs make much stronger claims than is allowed.
As from May  2012, it is likely that TCMs will have an alternative
regulatory route with the planned introduction of the regulation of
healthcare practitioners although, currently, this applies to the UK
only.
The THMRS is not the only regulatory pathway in Europe so it
is important for companies and researchers to determine what is
the most appropriate and beneﬁcial route for their product. Some
regulations which are presented in this review are still in legislation
process and may  change in due course.
2.2. China
In China,2 Chinese herbal products are governed by the State
Food and Drug Administration (SFDA) and can be registered
as functional food or drugs. Regulatory approval of functional
food is the responsibility of the Department of Food License
whereas that of Chinese herbal drugs is controlled by the Divi-
sion of TCMs & Ethno-Medicines under the Department of Drug
Registration.
Drugs in China cover not just chemical drugs but also traditional
medicines. According to Article 102 of the Drug Administration Law
of the People’s Republic of China (State Food and Drug Administration
P.R. China, 2001), the deﬁnition of drugs is as follows:
“Drugs refer to articles which are used in the prevention, treat-
ment and diagnosis of human diseases and intended for the
regulation of the physiological functions of human beings, for
which indications, usage and dosage are established, including
Chinese crude drugs, prepared slices of Chinese crude drugs,
traditional Chinese medicine preparations, chemical drugs sub-
stances and their preparations, antibiotics, biochemical drugs,
radioactive pharmaceuticals, serum, vaccines, blood products
and diagnostic agents.”
2.2.1. Laws and regulations
The Drug Administration Law of the People’s Republic of China
(Drug Administration Law), enacted in 2001, is the fundamental
law governing drug administration in China to ensure drug qual-
ity and safety for human beings, to protect the health of people
and their legitimate rights and interests in the use of drugs. The
Regulations for Implementation of the Drug Administration Law of
the People’s Republic of China are formulated in accordance with
the Drug Administration Law and provide legal framework for the
control over drug manufacturers, drug distributors, pharmaceu-
ticals in medical institutions, drug packaging, drug pricing and
advertising.
A unique feature of the regulatory system is the Regulations for
the Protection of TCM Products which provide administrative pro-
tections for TCM products manufactured within China (State Food
and Drug Administration P.R. China, 1993).
2.2.2. Distinction between TCM and natural medicinal products2 China refers to the mainland China. Chinese herbal products in Hong Kong and
Macau are governed by their domestic laws and regulations.
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scenario. 8 countries, including South Africa, Ghana and Nigeria,
have national laws relating to IPR and traditional medicine. ThereT.-P. Fan et al. / Journal of Ethn
ts safety, efﬁcacy and quality. According to this provision, Tradi-
ional Chinese Medicines refer to medicinal substances and their
reparations used under the guidance of traditional Chinese med-
cal theory; whereas natural medicinal products refer to natural
edicinal substances and their preparations used under the guid-
nce of modern medical theory. Traditional Chinese Medicines and
atural medicinal products can be classiﬁed into 9 categories as
ollows:
 Active ingredients and their preparations extracted from plants,
animals, minerals or other substances which have not been mar-
keted in China.
 Newly discovered crude drugs and their preparations.
 New substitutes to existing Chinese crude drugs.
New medicinal parts of existing crude drugs or their preparations.
Active fractions and their preparations extracted from plants,
animals, minerals or other substances which have not been mar-
keted in China.
Preparations of Chinese medicines and natural medicinal com-
pounds, which have not been marketed in China.
6.1. TCM combination preparations.
6.2. Natural medicinal combination preparations.
6.3. Combination preparations consisting Chinese medicines,
natural medicinal products and chemical drugs.
 Preparation with altered mode of drug delivery of marketed Chi-
nese medicines and natural medicinal products.
 Preparation with altered dosage form of marketed Chinese
medicines and natural medicinal products.
Generics.
.2.3. Drug standards
Both TCM and natural medicinal products must follow the
ational drug standards and provincial standards. The former
tandard is deﬁned by the Pharmacopoeia of PRC (ChP) and spec-
ﬁcations approved by SFDA. In the ChP, there are standards for
hinese prepared sliced crude drugs and TCM products. The stan-
ards for the herbal granules, being extracts for single herbs
r combination classical formulae, will be available in the 2015
dition. Provincial standards are monographs of Chinese materia
edica and processing of TCM herbal slices approved by individual
rovinces.
.2.4. Supplementary rules for TCM Registration
In order to follow the rules on the study of TCM, reﬂect the
istinguishing feature of the registration of TCM, regularise the
egistration of TCM and support the development of TCM and
edicine of Chinese minorities, SFDA issued the Supplementary
equirements on the Registration of TCM in accordance with rele-
ant requirements of Provisions for Drug Registration (State Food
nd Drug Administration P.R. China, 2008).
.2.4.1. Traditional or historical use. Under this Supplementary
equirement, TCM combination preparations were further divided
nto:.1.1 TCM combination preparations originated from historic, clas-
sic and well-known recipes.
.1.2 6.1.2 TCM combination preparations which indication is a
TCM syndrome.
.1.3 TCM combination preparations which indication is a combi-
nation of TCM syndrome and diseases.acology 140 (2012) 568– 586 573
The application data for marketing TCM combination prepara-
tion from historic,3 classic and well-known recipes may  be partially
exempted based on its formulation source, their composition, func-
tion, indication and manufacturing procedures. However, safety
data are compulsory.
2.2.5. Reasonability in accordance with TCM theory
The SFDA has expertise in assessing the reasonability of Chinese
herbal formulation. Depending on the registration classiﬁcation,
applicants may  be required to submit non-clinical safety data and
phase III clinical trials only. Clinical trials of the herbal formu-
lations have to be conducted in accredited centres for speciﬁc
disease/system in China. If the drug fails to demonstrate reasonable
formulation based on TCM theory, requirements for data submis-
sion may  follow that of natural medicinal products.
2.2.6. Summary
The supervision on TCM in China is as strict as that of chemi-
cal drugs and biological products. Registration of TCM is subject to
strict technical evaluation and clinical trial. Safety data are com-
pulsory although TCM that demonstrate historical use may  have
partial application data exempted.
2.3. Africa
A recent WHO  report (WHO Regional Report dated July 5th 2011
ref AFR/RC61/PR/2) on the status of traditional medicine in Africa
indicates the following:
• In 2000 only 10 African countries had laws on use of herbal
medicines. By 2010 the ﬁgure was  20 countries.
• In 2000 only 4 African countries had a registration system of
traditional healers. By 2010 the ﬁgure was  15 countries.
• In 2000 only 1 African country had issued a market authorisation
for traditional herbals. By 2010 the ﬁgure was 12 countries.
The countries which have done most to develop regulations for
both the manufacture and use of traditional herbal drugs but also
the regulations of traditional healers are:
• Egypt where all herbal medicines are regulated and manufac-
tured with licenses similar to Europe.
• Mali where traditional medicine is integrated into the health sys-
tem and traditional medicine is prescribed under the national
health system.
• Ghana where a herbal pharmacopoeia has been developed, com-
mercially manufactured herbal medicines are regulated by the
Food and Drugs Authority and traditional healers are organised
into a recognised national association.
Nigeria, Cameroon and Congo also now have national phar-
macopeias and issue market authorisations for commercially
manufactured herbal preparations. In many other African coun-
tries, including South Africa and Kenya, legislation regulating the
use of herbal medicines has been under discussion for many years
but has still not been passed by their governments.
The protection of the intellectual properties of traditional heal-
ers has become an increasingly important aspect of the regulatoryis, however, a wide gap between the existence of the legislation
3 Historical TCM formulae refer to those that are still widely used, of proven
therapeutic effect and was  documented before or during the Qing Dynasty (AD
1644–1912).
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nd the application of the law in practice (Association of African
edicinal Plants Standards; Denzil Phillips International Ltd.).
.4. Australia
.4.1. Introduction
The Therapeutic Goods Administration (TGA) is the main regu-
ator for Chinese material medica (CMM)  and related proprietary
hinese medicines (PCM) (TGA, 2011). Before importing or export-
ng CMM  and PCM, product sponsors must register or list their
roducts in the Australian Register of Therapeutic Goods (ARTG).
he TGA maintains the ARTG, a database that includes details of all
herapeutic goods that are imported into, supplied in, or exported
rom Australia. Once a product is successfully listed or registered,
GA will issue a certiﬁcate of listing/registering to sponsors who can
hen make the logistic arrangement for shipping these products.
.4.2. TGA regulatory aspects of complementary medicines
Generally, the therapeutic goods whose supply is regulated by
he TGA fall into three categories:
Medical devices.  Medical devices are items used on humans
for therapeutic beneﬁt and which generally have a physical or
mechanical effect on the body or are used to measure or monitor
functions of the body.
Registered medicines.  Registered medicines are those assessed
as having a higher level of risk. The degree of assessment and
regulation they undergo is rigorous and detailed, with spon-
sors being required to provide comprehensive safety, quality and
efﬁcacy data. They include all prescription medicines, most ‘over-
the-counter’ medicines and a small number of complementary
medicines.
Listed medicines.  Listed medicines are considered to have a lower
level of risk. They have established ingredients, usually with a
long history of use, such as vitamin and mineral products or
sunscreens. This category includes about 98% of complementary
medicines.
Examples of complementary medicines according to TGA (TGA,
011).
Medicinal products containing herbs, vitamins, minerals, and
nutritional supplements, homoeopathic medicines and cer-
tain aromatherapy products are referred to as ‘complementary
medicines’.
Complementary medicines comprise traditional medicines,
including traditional Chinese medicines, Ayurvedic medicines
and Australian Indigenous medicines.
Other terms sometimes used to describe complementary
medicines include ‘alternative medicines’, ‘natural medicines’
and ‘holistic medicines’.
Complementary medicines are generally available for use in self-
medication by consumers and can be obtained from retail outlets
such as pharmacies, supermarkets and health food stores.
Most complementary medicines are indicated for the relief of
symptoms of minor, self-limiting conditions; many are indi-
cated for maintaining health and wellbeing, or the promotion or
enhancement of health.
Source: TGA, www.tga.gov.au/industry/cm-basics-regulation-
verview.htm)..4.3. The growing use of complementary medicines in Australia
Surveys carried out in 1996 in Victoria and South Australia
ndicated about 50% of people had recently used alternativemacology 140 (2012) 568– 586
medicines. By early 2009, the National Institute of Complemen-
tary Medicine’s (NICM) ﬁgures indicated that 2/3 of Australians use
these medicines each year (Minister for Health and Family Services,
1996). Health professionals may  be contributing to the increased
usage in Australia. Research undertaken by the National Prescrib-
ing Service (NPS) in 2007 showed about 90% of general practitioners
had recommended at least one complementary medicine in the last
12 months and almost all surveyed community pharmacists had
recommended some kind of complementary medicine over that
period (NICM, 2009).
2.4.4. The reason for regulating complementary medicines
The belief that complementary medicines are safe because they
are ‘natural’ is considered by the TGA as an important risk. The risks
are relatively small when traditional medicines are used correctly,
but they are still there, and consumer understanding is generally
low. For example, a cross-sectional population survey conducted
in Australia found that less than half (46.6%) of traditional, herbal
medicine users were even aware that there could be potential
risks associated with product use. Not everything that is natural
is safe; traditional medicine products must be used judiciously and
as indicated, just like any other medication, and with awareness of
potential risk.
2.4.5. Development of the regulatory framework in Australia
The key events leading to regulatory frame work:
• Until the 1980s certain sorts of therapeutic goods were unreg-
ulated in Australia. This was  the case with most therapeutic
devices and with complementary medicines for which there were
increasing concerns about quality, safety and the ‘extravagant
therapeutic claims’ that were being made.
• National regulation of complementary medicines commenced
with the Therapeutic Goods Act 1989. Section 9A of the Act requires
the Secretary of Department of Health & Ageing (DoHA) to main-
tain a register of therapeutic goods. This is the Australian Register
of Therapeutic Goods (ARTG), which is at the heart of therapeutic
goods regulation in Australia (see the box below).
• A therapeutic good must be on the ARTG before it can be imported
into, supplied in Australia or exported, unless it is in a special
category of exempt or excluded goods. The importer or manu-
facturer of the goods (under the Act, the ‘sponsor’) is responsible
for applying to the TGA to have their goods included in the ARTG.
The sponsor of a therapeutic good included in the ARTG must be
an Australian resident and/or doing business in Australia.
2.4.6. The Australian Register of Therapeutic Goods
The ARTG is established under the Act. The Secretary of DoHA is
required to maintain the ARTG, comprising three parts:
(1) Registered medicines.  These are higher-risk items whose efﬁcacy
must be demonstrated before they can be registered. The Act
requires them to be evaluated for quality, safety and efﬁcacy
before they can be registered. They must display an ‘AUST R’
number on their label as proof of registration.
(2) Listed medicines.  These can be listed unless they fail to comply
with quality and safety criteria. They are not evaluated for efﬁ-
cacy. They are generally lower-risk items, usually self-selected
by consumers for self-treatment. They must display an ‘AUST L’
number on their label as proof of listing. Medicines for export
only are listed on the ARTG.
(3) Medical devices.  These include a wide range of products such
as medical gloves, bandages, syringes, condoms, contact lenses,
in vitro diagnostic devices, disinfectants, X-ray equipment, sur-
gical lasers, pacemakers, dialysis equipment, baby incubators
and heart valves.
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Medicines included in the ARTG are divided into three broad
ategories:
1) Prescription medicines. These are medicines available only upon
prescription by a qualiﬁed health practitioner, usually for a seri-
ous illness. They must be registered on the ARTG, will usually
contain an active ingredient which is a ‘scheduled’ substance
(that is, included in the Standard for the Uniform Scheduling of
Medicines and Poisons (SUSMP))46 and their use may  involve
risks.
2) Over-the-counter (OTC) medicines.  These items, also registered
on the ARTG, include mild analgesics, cough and cold prepa-
rations and anti-fungal creams. OTC medicines generally have
active ingredients less potent than those used in prescription
medicines.
3) Complementary medicines (sometimes called ‘complemen-
tary and alternative medicines’, ‘CAM’). Most complementary
medicines are listed on the ARTG and include vitamins, min-
erals, Chinese traditional medicines, herbal, aromatherapy and
homeopathic products.
Source: Therapeutic Goods Act 1991)
.5. Brazil
.5.1. Introduction
Herbal medicine has been regulated in Brazil in some form or
nother since 1967 with effective regulation being implemented
ince 2000. Then in 2006 the National Policy of Integrative and
omplementary Practices (PNPIC) in the Brazilian Uniﬁed Health
ystem (SUS) and The National Policy of Medicinal Plants and
erbal Medicines (PNPMF) were launched. Based on these policies,
NVISA (the Brazilian Health Surveillance Agency) amended the
egulations applicable to herbal medicines. Previously there were
ve key regulations but these have now been succeeded by the
ecently published RDC 14/10 (Carvalho et al., 2011; WHO  Geneva
011, 2011).
.5.2. Safety, efﬁcacy and traditional use
Herbal products are categorised as ‘herbal drugs’ (prescrip-
ion and over-the-counter); functional foods, probiotics, bioactive
ubstances and cosmetics. Medical claims are only allowed if the
roduct is registered as a herbal medicine. It is worth noting that
erbal medicines have the same status as any other medicine. This
eans that they can only be produced by GMP-certiﬁed facilities
and the company must employ a qualiﬁed pharmacist). Safety and
fﬁcacy must be demonstrated by pre-clinical and clinical data,
iterature, an entry in the “list of simpliﬁed registration of herbal
edicines” or evidence of traditional use. Traditional use must con-
rm the safety and efﬁcacy of a product and document at least
0 years of use. Farmacopéia brasileira is Brazil’s Pharmacopoeia
includes their national monographs) and is legally binding.
.5.3. Quality control
It is a requirement for various tests to be carried out to demon-
trate product quality. These tests should conﬁrm, for example, the
lant genus and levels of contaminants (e.g. fungi) within accept-
ble limits. RDC 14/09 states the requirements for quality assurance
nd in particular, the reproducibility of herbal medicines. Any com-
any submitting a herbal medicine dossier for registration should
se the methodologies included in the pharmacopeias recognised
y ANVISA for quality control of herbal materials, excipients and
edicine. If the pharmacopeias are not followed then the company
s required to validate the methodologies they have used (ANVISA,
008).acology 140 (2012) 568– 586 575
2.5.4. Other regulations
These include
• Restriction of sale criteria i.e. is the medicine to be sold as a pre-
scription medicine or not (Brasil, 2003b).
• Stability study guide (Brasil, 2005a).
• GMP, quality control and outsourcing of storage (Brasil, 2005b,
2007).
• Advertising (Brasil, 2008c).
• Standardisation of Package Leaﬂet (RDC 47/09)).
The list, RDC 138/03, itemises those medicinal products which
do not require a prescription. If the indication described on the
product is not included in RDC 138/03 then it can be marketed
under prescription only (Brasil, 2003b).
RE 01/05 provides information on stability requirements for
both accelerated and long lasting mode with the results determin-
ing the product’s expiry date and appropriate storage conditions
(Brazilian Government, 2010).
2.6. Canada
Canada is one of the countries in the western world that has
better established system in regulating natural health products
(NHPs). In Canada, NHPs are deﬁned as vitamin and mineral sup-
plements; herb and plant-based remedies; traditional medicines
like TCM or Ayurvedic (Indian) Medicines; omega 3 and essential
fatty acids; probiotics; homeopathic medicines.
All NHPs sold in Canada are subject to the Natural Health Prod-
ucts Regulations (The Government of Canada, 2003), which came
into force on January 1, 2004. Under this regulation, all producers
of NHPs need to apply for licenses before selling them in Canada.
To apply for a licence, the person or company shall submit an appli-
cation to Natural Health Products Directorate (NHPD), Minister of
Health Canada (Health Canada, 2011c)  with a package of infor-
mation. Among others, the application requires the information
for each medicinal ingredient contained in the NHP, including its
quantity per dosage unit, potency, source material and a statement
indicating whether it is synthetically manufactured. It also requires
information for non-medicinal ingredients and recommended use.
The safety and efﬁcacy of NHPs and their health claims must be
supported by proper evidence. It is interesting to note that evi-
dence is not necessarily from clinical trial data but can also be
references to published studies, journals, pharmacopoeias and tra-
ditional resources. The type and amount of supporting evidence
required depends on the proposed health claim of the product and
its overall risks.
There is a compendium of monographs established by NHPD
(Health Canada, 2011d). The NHPD product licensing system allows
applicants to reference the monographs listed in the compendium
in support of the safety and efﬁcacy of their products, rather than
providing evidence for ingredients that are already known to be
safe and efﬁcacious when used under the conditions speciﬁed in
the monographs.
Once Health Canada has assessed a product and decided it is
safe, effective and of high quality, it issues a product licence along
with an eight-digit Natural Product Number (NPN) or Homeo-
pathic Medicine Number (DIN-HM), which must appear on the
label. The licensing procedure is to be completed within 60 days
after the day on which the application is submitted unless addi-
tional information is required by the NHPD. It might be important
to notice that the licensing requirements of the Natural Health
Products Regulations only apply to any person or company that man-
ufactures, packages, labels and/or imports NHPs for commercial
sale in Canada. They do not apply to health care practitioners who
compound products on an individual basis for their patients, or
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o retailers of NHPs. In addition, because Health Canada has not
et evaluated all natural health products currently on the mar-
et, products with exemption numbers can also legally be sold
n Canada. The exemption number will be listed on the product
abel in the form EN-XXXXXX. You can search for licensed natu-
al health products using Health Canada’s Licensed Natural Health
roducts Database (Health Canada, 2011a), or for exempted nat-
ral health products using Health Canada’s Exempted Products
atabase (Health Canada, 2010). On the other hand, all Cana-
ian manufacturers, packagers, labellers, and importers of natural
ealth products must have site licenses. To get a licence, sites
ust maintain proper distribution records, have proper proce-
ures for product recalls and for the handling, storage and delivery
f their products, and demonstrate that they meet good man-
facturing practice requirements. As of December 31, 2010, the
HPD has issued 25,919 product licences (representing over 34,900
roducts); 1120 site licences; and 6795 exemption numbers (rep-
esenting over 8300 products). Since 2009, there are about 8000
ew applications submitted each year in Canada (Health Canada,
011b).
.7. Japan
.7.1. Introduction
Kampo is the Japanese traditional medicine which is based on
raditional Chinese medicine. Although Kampo has its roots in
hina, it is a product of Japanese culture and experience. Chinese
edicine was ﬁrst introduced to Japan in the 4th century. Japanese
ractitioners gradually reﬁned and improved the original formu-
ae. After the 17th century, many of the original formulae were
alidated through clinical experience, which laid the foundation of
ampo medicine (Goda, 2006).
.7.2. Regulations of herbal medicines
The Ministry of Health, Labor and Welfare is the regulatory
gency in Japan responsible for herbal medicines. Pharmaceuti-
al administration in Japan is regulated according to a number of
aws among which the Pharmaceutical Affairs Law is the supreme
aw. Issued in the 1950, the Pharmaceutical Affairs Law documented
ational laws and regulations on traditional medicines and its
urpose is to regulate matters pertaining to drugs, quasi-drugs,
osmetics and medical devices in order to ensure their quality, efﬁ-
acy and safety. It also promotes the drug development for orphan
iseases (Saito, 2000).
.7.3. Herbal medicine as prescription drugs or OTC drugs
Depending on the medical claims, herbal medicines may  be
pproved as prescription drug or OTC drugs. Prescription drugs
ave to be produced according to the ofﬁcial quality standards as
equired by law. As for the Japanese OTC drugs, they are divided into
apanese traditional medicines, ‘Kampo’ formula, phytomedicines
nd multi-vitamin preparations. To date, more than 200 ‘Kampo’
ormulae have been listed for insurance reimbursement. Herbal
rude drugs combined with chemical drugs were also accepted,
ubject to quality, safety and efﬁcacy tests, as CNS drugs, cold
emedies, antipyretics, analgesics, topical drugs, anti-inﬂammatory
rugs, gastrointestinal drugs, cardiovascular drugs and urogenital
rugs (Saito, 2000).
.7.4. Prescription-to-OTC Switch
Some products, even though originating from a recognisedKampo’ formula, may  also be deﬁned as an OTC drug depending on
ts composition, doses, efﬁcacy and direction of use. ‘Shosaiko-To’
s a typical example of a product which can be both a prescription
rug and OTC in the Japanese market (Saito, 2000).macology 140 (2012) 568– 586
2.7.5. Japanese Pharmacopoeia
In Kampo medicine, the decoction formula generally consists
of 2–15 different crude drugs. Nowadays, Kampo preparations are
mainly distributed in the form of ready-made granules, powders
or tablets which contain the spray-dried decoction (dry extract).
Therefore, dry extract was selected for admission to the Japanese
Pharmacopoeia (Goda, 2006).
The Japanese Pharmacopoeia is divided into 2 sections, namely
the crude drugs and their related preparations (Section II) and oth-
ers (Section I). Therefore, Section II of the Japanese Pharmacopoeia
contains the monographs of crude drugs and their related prepa-
rations only including that of a number of Kampo formula extract
(Goda, 2006). The pharmacopoeia includes herbal crude drugs of
both Japanese and European origins.
The Japanese Pharmacopoeia is legally binding. Regulatory
requirements for manufacturing are the same GMP rules that apply
to conventional pharmaceuticals; these requirements are part of
the following regulations: Pharmaceutical Affairs Law, Regulations
for Manufacturing Control and Quality Control of Drugs and Quasi
Drugs and Regulations for Buildings and Facilities for Pharmacies.
The control mechanisms used to ensure the implementation of
these requirements are the same as those used for conventional
pharmaceuticals; however, details are not available. The regula-
tory requirements for safety are the same requirements that apply
to conventional pharmaceuticals. To ensure the implementation of
these requirements, the same rules of approval review, GMP  and
post-marketing surveillance are used for herbal medicines as for
conventional pharmaceuticals (WHO, 2005).
2.7.6. Summary
In Japan, regulations for herbal medicines are the same as that
for conventional pharmaceuticals. Herbal medicines are regulated
as prescription and over-the-counter medicines, dietary supple-
ments (called “health foods”) and functional foods. By law, medical,
nutrient content and structure/function claims may  be made for
herbal medicines. Currently, there is an approval system rather
than a registration system; at least 1469 herbal medicines have
been approved (WHO, 2005).
2.8. Russia
2.8.1. Introduction
Phytotherapy is a separate branch of medicine in Russia and
herbal medicinal preparations (HMP) are ofﬁcial medicaments.
More than 600 HMP  have been registered for medication and
included in the Governmental Register of Medicinal preparation
(Shikov et al., 2011; Register Russia, 2011).
2.8.2. Laws and regulations
All aspects relating to the development, preclinical and clin-
ical studies, evaluation, state registration, standardisation and
quality control, manufacturing, preparation, storing, transport-
ing, importing and exporting, advertising, releasing, selling, using,
and disposing of pharmaceutical preparations (including HMP) are
regulated by Federal Law No. 61 FZ (dated 12.04.2010) “About
circulation of drugs”. In case preparations of TCM have medici-
nal indication they are recognised as HMP  and governed by above
mentioned law.
A drug master ﬁle for a HMP  for the purpose of state registration
should be prepared according to the Federal Law No. 61 FZ and
regulations and the legislation, including• Decree No. 759n of Ministry of Public Health and Social Devel-
opment of Russian Federation dated on August 26th 2010
“Procedure for submission of the documents necessary for the
opharm
•
•
2
t
h
p
c
1
2
3
4
5
2
cT.-P. Fan et al. / Journal of Ethn
state registration forming the drug master ﬁle for a pharmaceu-
tical product created for medical use”.
Decree No. 750n of Ministry of Public Health and Social Develop-
ment Russian Federation dated on August 26th 2010 “The rules
governing the evaluation of pharmaceutical products for medical
use and the decision of the expert committee”.
Decree No. 388 of Ministry of Public Health and Social Develop-
ment of Russian Federation dated on 01.11.2001. About the state
quality standards of medicinal preparations.
.8.3. Classiﬁcation of HMP  in Russian Federation
Herbal medicinal preparation is the ﬁnished product and per-
ains to a medical preparation containing herbal materials and/or
erbal preparations as its active ingredients. Depending on the
rocessing method used, the pharmaceutical formulations can be
lassiﬁed into the following categories (Severtsev et al., 2003):
. Medicinal plant materials are dried or sometimes newly gath-
ered parts of medicinal plants (rarely, integral plants) used for
the production of medical drugs. Medical species are mixtures
of a few kinds of crushed or integral plant materials with salts
and ethers as additives.
. Summarised non-reﬁned or galenic formulations contain, along
with biologically active substances, a number of concomitant
substances. In the course of production, inactive ingredients are
removed from galenic formulations. These include herb infu-
sions and decoctions, tinctures, extracts and elixirs.
• Infusions and decoctions are liquid medicinal preparations
representing aqueous extracts from medicinal plant materi-
als, as well as aqueous solutions of dried or liquid extractions
(concentrates).
• Tinctures are medicinal formulations in the form of alcoholic
and aqueous/alcoholic extracts from medicinal plant materials
(1:5 or 1:10) produced with no heating or removal of extrac-
tant.
• Extracts are concentrated extractions from medicinal plant
materials in the form of liquid (1:1), stick (moisture < 25%), or
dried (moisture < 5%) mass.
• Elixirs are liquid medicinal formulations in the form of a
transparent mixture of alcoholic/aqueous extractions from
medicinal plant materials with medical drugs, sugars and ﬂa-
vors as additives.
. Novo-galenic formulations are phyto-preparations containing
a mixture of biologically active substances that are free from
inert and concomitant ingredients. They contain a mixture of
alkaloids, coumarins, etc. Novo-galenic preparations also include
such substances as ﬂamine (dried extract of immortelle ﬂowers
containing ﬂavonoids), ergotal (mixture of ergot alkaloid phos-
phates), adonisid (extracted from Coronaria grass), etc.
. Active pharmaceutical ingredients (API) – individual compounds
isolated from plants (serotonin, morphine, rutin, lysergin, etc.).
These compounds have direct action and a majority of them are
used for the preparation of injection formulations.
. Combined phyto-preparations contain, along with the sub-
stances extracted from plants, synthetic, endocrine and other
types of ingredients such as “Allokhol” (based on dry extracts
from garlic and nettle with coagulated active coal as additive),
“Besalol” (contains viscous extract of belladonna and phenylsal-
icylate), “Valocormyde” (based on the tincture of valerian, lily of
the valley and belladonna with sodium bromide and menthol as
additives), etc..8.4. Registration of medicinal preparations and HMP
The registration procedure for pharmaceutical preparations is
learly described, including all steps and deadlines in Federal Lawacology 140 (2012) 568– 586 577
No. 61. The maximum period of registration is 210 days. The
application requirements for state registration of pharmaceutical
preparations and documents of the drug master ﬁle are the same
for domestic and foreign manufacturers. HMP  is assessed for its
safety, efﬁcacy and quality.
The activities related to the evaluation of pharmaceutical prepa-
rations in the framework of the Federal Law are implemented
by the Federal State Organization FGU “National Center of exper-
tise of preparation for medicinal application” of the Ministry of
Public Health and Social Development of the Russian Federation.
Anything related to pharmaceutical preparations comes under the
jurisdiction of the “Centre for Evaluation and Control of Finished
Pharmaceutical Products” which comprises of four divisions and
one test center for pharmaceutical products quality evaluation.
All applications for registration of pharmaceutical preparation
in Russian Federation are subject to evaluation (Decree No. 750n of
Ministry of Public Health and Social Development Russian Federa-
tion dated on August 26th 2010).
2.8.5. Drug standards
Pharmaceutical preparations must follow the national drug
standard. State standard OST 91500.001-00 “Standards for qual-
ity of medicinal drugs – basic provisions” was introduced in the
Russian Federation by the Decree No. 388 of Ministry of Public
Health and Social Development of Russian Federation dated on
01.11.2001. This standard sets out the categories, development
procedures, wordings, ﬁling, expertise, approval and designation
of quality standards for pharmaceutical preparations. The provi-
sions of the standards are binding upon developers and producers
of medicinal/herbal drugs, as well as upon the companies involved
in the expertise of the quality standards of medicinal drugs.
The 12th State Pharmacopoeia of Russian Federation is main
state quality standard of pharmaceutical preparations. The ﬁrst part
was  published in 2007 and it includes the description of analysis
methods and pharmaceutical substances. The second part includes
speciﬁc pharmacopoeial monographs for individual drugs and it
was  submitted for approval by the Ministry of Public Health and
Social Development of the Russian Federation in 2010 (Severtsev
et al., 2003; Shikov et al., 2011).
2.8.6. Summary
Herbal medicinal preparations are ofﬁcial medicaments in
Russia and regulations for HMP  are the same as that for pharmaceu-
ticals. More than 600 HMP  have been registered for medication and
included in the Governmental Register of Medicinal preparation.
All aspects of handling of pharmaceutical preparations (including
HMP) are regulated by Federal Law No. 61 FZ “About circulation of
drugs”. In case preparations of TCM have medicinal indication they
are recognised as HMP  and governed by above-mentioned law.
2.9. South Korea
2.9.1. Introduction
Although the medical system in Korea is divided into two sys-
tems: a modern medical system and a Korean traditional medical
system, medicines are controlled by a single regulatory system
established by the Pharmaceutical Affairs Act. The Korea Food and
Drug Administration (KFDA) is in charge of establishing standards
and pre-market approval, post-market inspection, and manage-
ment of the product quality system for herbal medicines.
2.9.2. Regulation
The Pharmaceutical Affairs Act, passed in 1954, deals with phar-
maceutical affairs including herbal medicines. Other regulations
concerning the control of herbal medicines are ‘Regulations on the
demand/supply, distribution, and product management of herbal
5 ophar
m
u
2
a
m
s
s
t
t
m
h
v
b
c
t
c
a
g
c
m
l
t
o
i
a
t
n
m
t
o
i
m
s
q
2
p
t
t
w
i
M
d
2
f
s
o
t
2
a
t
A
o
m
s78 T.-P. Fan et al. / Journal of Ethn
edicines’ (Ministry of Health and Welfare Notiﬁcation) and ‘Reg-
lations for Imported Medicines’ (KFDA Notiﬁcation).
.9.3. Standardisation of herbal medicines in Korea
Standards for commonly used herbal materials and preparations
re included in the ‘Korean Pharmacopoeia’, ‘Korean Herbal Phar-
acopoeia’, and ‘Korean Pharmaceutical Codex’. In terms of the
afety of herbal medicines, the amount of hazardous substances
uch as heavy metals, pesticides, and aﬂatoxins are restricted by
he ‘Regulations on Limits and Test Methods for Residues and Con-
aminants in Herbal Medicines’.
Traditional medicine (TM) has a long history as an important
eans in curing diseases in Eastern Asia. Despite this fact, TM
as been often disregarded as non-scientiﬁc and even excluded in
iew of western medicine. Recently, however, new evidence has
een discovered through elaborate scientiﬁc approaches with some
ases even successfully leading to new drug development, both at
he level of extracts and pure substances. The formulae for TMs
omprised a single herb or several herbs have great potential as
ctive ingredients of drugs. Nevertheless, the ambiguity of the ori-
ins of the herbs makes them more difﬁcult to be utilised for either
linical or industrial purposes, and thus, both standardisation and
odernisation of TMs  is essential.
Since 2005, a collaborative study has been conducted to estab-
ish a method for the standardisation of herbal medicines through
he support of the Korea Food & Drug Administration (KFDA). One
f the speciﬁc aims of this project is to establish the unique chem-
cal principles of herbal medicines based on their pharmacological
ctivities. Thus far, a total of 64 herbal medicines have been inves-
igated and about 30 more plant drugs will be investigated over the
ext four years.
Many facts about medicinal plants have been identiﬁed and new
ethods for quality control have been reported. Nevertheless, all
hese things cannot be included in the pharmacopoeia. The purpose
f this research project is to lay a foundation for workers engaged
n this area to discriminate between inferior and superior herbal
edicines using scientiﬁc methods. Once the research project is
uccessfully completed, herbal medicines with a high standard of
uality are expected to be distributed on the market.
.9.4. Pre-marketing approval of herbal medicines
To manufacture herbal medicinal products, one must obtain the
ermission of the KFDA by submitting data on the standards and
est methods, safety, and efﬁcacy according to the ‘Regulations for
he approval and registration of herbal medicines’. Preparations
ith the same ingredients, dosages, and efﬁcacy that are included
n the ten traditional Korean medicinal references, indicated by the
inistry of Health and Welfare Notiﬁcation, do not need to submit
ata on the safety and efﬁcacy of the preparation.
.9.5. Herbal materials as health functional foods
Herbal medicinal materials have also been used as a source of
ood and health functional foods. A lot of health functional foods
uch as red ginseng products are used in Korea. The manufacturing
f health functional foods must be approved by the KFDA according
o the ‘Health Functional Food Act’.
.9.6. Summary
For the purposes of consumption, herbal materials can be used
s sources of food, health functional foods, or drugs. In each case,
hey are controlled by different legal systems, the ‘Food Sanitation
ct’ (food), ‘Health Functional Food Act’ (health functional food),
r ‘Pharmaceutical Affairs Act’ (medicine). As medicine, herbal
edicines need to have a high standard of quality as well as be
afe and have efﬁcacy.macology 140 (2012) 568– 586
2.10. Taiwan
In Taiwan, regulations on TCM are under the jurisdiction of the
Committee on Chinese Medicine and Pharmacy (CCMP), Depart-
ment of Health (DoH). The national health insurance (NHI) has been
implemented in Taiwan since 1995, covering western medicine,
TCM and dentistry. By the year 2005, all TCM pharmaceutical man-
ufacturing facilities have met  GMP  standards as required by the
government. Currently, there are 117 TCM pharmaceutical manu-
facturing facilities in Taiwan producing various preparations such
as concentrated extract granules or powder, pills, capsules. How-
ever, only concentrated extract granules and powders are covered
by the insurance. Decoctions of traditional herbs are not covered
by NHI. In other words, patients receiving raw herbal decoctions
have to pay out of their own pockets. Moreover, only traditional
formulae that have been listed in classical TCM literature can apply
for registration and licensing without clinical efﬁcacy/safety data.
Registration and licensing of traditional formulae require them to
meet the DoH’s “Standards of Examination and Registration for
Medicines (revised in September, 2005, in accordance with Para-
graph 4 of the Pharmaceutical Act)”. With increasing concerns from
the consumers, as of August, 2011, the DoH issued a rule that all
concentrated Chinese medicinal preparations (including formulae
and single herbs) should contain total heavy metals no more than
30 ppm; additionally total microbe number should be less than
105 cfu/g, and Escherichia coli or Salmonella spp. should be unde-
tected.
All new or innovated formulae must apply for registration and
licensing according to the “Guideline on Examination and Reg-
istration of New Chinese Medicines”, issued by the DoH in June
1998. Brieﬂy, for Chinese medicines listed in classical Chinese TCM
literatures to apply for Chinese medicines with new therapeutic
efﬁcacies (indications) or new administrating routes must provide
data on clinical efﬁcacy. For Chinese medicines unlisted in classical
TCM literatures, data on clinical efﬁcacy, safety and quality control
must be provided at the time of application. Eighteen TCM clini-
cal trial centers have been set up to perform clinical trials on TCM
preparations. Similarly, application for registration and licensing
of botanical drugs (not traditional Chinese herbs) should generally
provide data on clinical efﬁcacy, safety and quality control (CCMP,
2011).
2.11. The United States
2.11.1. Introduction
In the United States, FDA regulated product categories under the
Federal Food, Drug, and Cosmetic Act (“the Act”) or Public Health
Service Act (“PHS Act”) included the following:
• Cosmetic;
• Device;
• Dietary supplement;
• Drug, as well as “new drug” and “new animal drug;”
• Food; and
• Food additive.
A botanical product (including those marketed in other coun-
tries as herbal medicines/Chinese herbal medicines) may  be subject
to regulation as a biological product, cosmetic, drug, device, or food
(including food additives and dietary supplements) under the Act
or the PHS Act (FDA, 2011b).
These statutory deﬁnitions also cover herbal medicine/botanical
products. Neither the Act nor the PHS Act exempts CAM products
from regulation. This means, for example, if a person decides to
produce and sell a Goji juice product to promote optimal health,
that product is a food subject to the requirements for foods in the
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ct and FDA regulations, including the hazard analysis and criti-
al control point (HACCP) system requirements for juices in 21 CFR
art 120. If the Goji juice is intended for use as part of a disease
reatment regimen and intended to label the product’s function
s such instead of for the general wellness, the Goji juice prod-
ct would also be subject to regulation as a drug under the Act.
or the Goji product to become an approved new drug for a dis-
ase treatment, then the sponsor should reference FDA’s Guidance
or Industry-Botanical Drug Products to demonstrate its safety and
fﬁcacy through well-designed clinical studies, and meet other reg-
latory requirements for new drugs (e.g. assurance of quality and
onsistency of the product).
.11.2. Botanicals as FDA regulated products
Cosmetic
Cosmetic, regulated by FDA’s CFSAN, the center also regulates
food, food additives, and dietary supplement. Many botanicals are
used in cosmetics without particularly describe their functions on
the label. Green tea and Aloe vera are among the commonly used
ingredients in cosmetics.
Food
Some Chinese herbs are marketed and available as regular
food/spice e.g. ginger, star anis, and garlic. Some TCM herbs that
are not commonly used as spices in the West may  also be found
from ethic stores (and Asian markets) e.g. Ginseng, Astragalus
root, Dan-Kuei (Dang-Gui). Certain food may  be permitted to bare
general “health claims”.
Dietary supplement
Under Dietary Supplement Health and Education Act (DSHEA,
1994), most of the Chinese herbs (except several of the most toxic
herbs, minerals, and certain animal products) and many tradi-
tional Chinese medicine products are permitted to be marketed as
dietary supplements, provided that those products comply with
the labelling requirements for dietary supplements. CFSAN does
not publish the list of grandfathered herbal dietary supplements,
but the book Herbs of Commerce (1992) is a common reference by
industry as one of the references to indicate that an herb has been
marketed before DESHA becoming effective. For those TCM prod-
ucts marketed in the US, the disease claims from the traditional
uses are not permitted on the label of the products. Otherwise,
the marketer/manufacture will be considered as marketing of
non-approved drugs.
Newly formulated TCM products can be marketed as dietary
supplements in the US, but the sponsor is recommended to
check CFSAN’s website or contact CFSAN directly to determine
whether a new dietary ingredient (NDI) is needed. For exam-
ple, pomegranate skin has been used in TCM, and the herb can
be marketed as a dietary supplement. However, a concentrated
extract of pomegranate skin was requested to be qualiﬁed as a
NDI to demonstrate the proposed dose of the product for safety.
The sponsor eventually provide data to conﬁrm that the daily
dose of the pomegranate extract contains equivalent amount of
polyphenols as 8 oz of pomegranate juice, and thus the product
was determined to be safe for being marketed as an NDI.
Acupuncturists/herbalists in the US, use TCM products based
on a one-to-one practitioner-client consultation. These products
are regulated as dietary supplements without any labeled dis-
ease claims on the product labels. FDA will take actions on certain
herbal products, if the product is deems unsafe (e.g. contain cer-
tain toxic or otherwise banned herbs e.g. Ephedra).
Drug
In 2000 FDA published the Guidance for Industry-Botanical
Drug Products (draft) to illustrate its current thinking on how to
develop a botanical mixture into a botanical new drug. Accord-
ing to the principles of the Guidance (ﬁnalised in 2004) (FDA,
2011a), a botanical product, including those used in CAM oracology 140 (2012) 568– 586 579
Chinese medicine, can be further developed through clinical tri-
als and non-clinical studies to become an FDA approved drug
through investigational new drug application (IND) and new drug
application (NDA) processes without further puriﬁcation nor
identiﬁcation of active compounds from the botanical mixture.
FDA recognised and reference previous human use of botani-
cal (herbal) products and foreign clinical trial data as part of the
safety and efﬁcacy evaluation. However, it is unlikely that botan-
ical drugs can be approved based solely on “traditional use”.
• Since the publication of the guidance, over 400 pre-INDs and INDs
have been submitted to CDER, FDA, most of which are intended
for phase I and II studies to investigate the preliminary safety
(or efﬁcacy) of the products, few are intended for phase III tri-
als which will have a potential of leading to botanical NDAs.
So far, only one botanical NDA has been submitted and subse-
quently approved. About a quarter of the INDs are intended to
study botanical products that are originated with TCM herbs.
2.11.3. Discussion and conclusions
Herbal medicines/botanicals are not deﬁned as regulatory prod-
uct categories under the Act or PHS Act. FDA regulates TCM products
as either food, food additive, dietary supplements, cosmetics, drugs,
devices, or biologics, according to the Act, and PHS. Act. Most TCM
products (include TCM raw herbs) are currently marketed/used
in the US as food, dietary supplements, and/or as ingredients of
cosmetics.
TCM products and raw herbs can be further developed as new
drugs through IND/NDA processes. FDA references previous human
use in TCM and other herbal medicine systems to speed up early
phase clinical trials of botanicals without requesting standard ani-
mal  toxicology data, if the previous human use of the product is
deemed to be safe. However, the overall requirements for NDA of
a botanical drug product are not signiﬁcantly different from those
of pure small molecule new molecular entities (NMEs). FDA recog-
nises the challenges to demonstrate the quality and therapeutic
consistency of a complex botanical product. The current thinking at
the FDA is to adopt comprehensive approaches, which may  include
one or more of the following, robust chemistry, manufacturing, and
control (CMC), clinically relevant bioassays, multiple-batch clini-
cal trials, based on the particular situations of the to-be-studied
botanical product (Chen et al., 2008).
3. General discussion
A major challenge is how to deﬁne an herbal medicine and,
in particular, a traditional herbal medicine. For example, garlic
(Allium sativum) is eaten as a food/spice throughout the world and
is often used knowingly to help lower cholesterol and to treat
certain cancer symptoms. In Europe, garlic is classiﬁed as a food,
herbal supplement, herbal medicine, food supplement and as a
pharmaceutical medicine. In Brazil, garlic is classiﬁed as a “phy-
totherapeutic agent”!
An important question arising from our research is whether it
is possible to develop a model for universal harmonised registra-
tion of herbals. It is conceivable that harmonisation of monographic
standard and mutual recognition of herbals across the globe may  be
an easier way to proceed. For example, the root of Polygala tenuifo-
lia (a Chinese materia medica called “Yuanzhi” in Chinese) has been
widely used as a memory enhancer for people in Asian countries
for many years (Xu et al., 2011), and it is also included in many
traditional prescriptions used for treatment of amnesia and demen-
tia. However, other Polygala species in Europe have no recorded
medicinal applications, except Proteus vulgaris (known as Common
Milkwort), the whole herb being used as an infusion to increase
the ﬂow of a nursing mother’s milk. If different Polygala species
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n EU have memory-enhancing effects like Polygola tenuifolia root
sed in China, this might be used for the demonstration of tradi-
ional use under 30/15 year rule. It was proposed that interested
arties should contact their National Authority and propose to the
uropean Directorate for Quality Medicines & Healthcare (EDQM)
or the inclusion of relevant Chinese herbs into the EU pharma-
opeia monographs. In a similar manner, European herbs can be
onsidered for inclusion in Chinese Pharmacopeia. Presently the
egistration procedures in the EU and China for herbal products are
uite different (see Figs. 2–4 shown in Appendix).
It is noteworthy that EDQM Working Group for TCM is estab-
ishing monographs for CMM  with the Hong Kong Chinese Materia
edica Standards Ofﬁce (HKCMMS – where an International Advi-
ory Board is overseeing the standards involving the advices from
ecognised academic, scientists working in registration bodies and
xperts from Australia, Canada, China, EU, Japan, Thailand and USA)
ith Pharmacopoeia of the People’s Republic of China (Chinese
harmacopoeia). This may  eventually produce a path for harmon-
sation of ofﬁcial standards of CMM,  the starting materials for
anufacturing of Chinese herbal medicines and TCM practice.
. Concluding remarks
As emphasised in the Introductory Paper (Uzuner et al., 2012)
f the GP-TCM Journal of Ethnopharmacology special issue, “good
ractice” is further deﬁned as: (i) collaboration and sharing, and
ii) striving for consensus while respecting differences of opinion.
he regulatory issues for registration of herbal products are compli-
ated among the countries and regions worldwide (see Comparison
ables 2 and 3 in Appendix).  The information summarised in the
ext is for reference only. Before taking any regulatory action, read-
rs are advised to consult current ofﬁcial legislation and guidance
nd/or to seek appropriate professional advice.
The WHO  is well placed to co-ordinate a consultation process
ith the aim of putting forward suggestions for harmonisation to
ey regulatory agencies etc. As a start, through WHO  Collaborat-
ng Centres for Traditional Medicine, the following issues could be
iscussed, agreed and implemented:
the deﬁnition for “traditional herbal remedy” – in some coun-
tries they are seen as ‘food supplements’ whilst in others they
are deemed to be ‘medicines’ (requiring a full product licence);
the deﬁnition and English terminology of raw herbs, ‘paozhi’
(processing of Chinese material medica) or prepared herbs and
‘granule’ extracts;macology 140 (2012) 568– 586
• documentation/data and requirements are acceptable globally
e.g. suggest removing the 15 year rule for traditional use in Europe
and simply retain the 30 year rule whether it be in China, India,
Africa, Europe, etc.;
• GxP activities to be of the same standard worldwide;
• more stringent post-marketing surveillance i.e. pharmacovigi-
lance;
Given the exponential decline of the R&D productivity of
pharmaceuticals from 1950 to 2008 and the WHO’s encouraging
strategy on traditional medicine, it seems that herbal industry, if
properly regulated, would play an increasingly important role in
global healthcare. Through international collaborations, we may  be
able to achieve regulation without borders, and today’s herbs may
become, or evolve into, tomorrow’s medicines.
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Appendix.Fig. 1. The CTD triangle.
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Fig. 2. Registration ﬂowchart of natural products in EU.
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Fig. 3. Registration ﬂowchart for traditional herbal medicinal products in EU.
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Fig. 4. Registration ﬂowchart in China.
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Table  1
Dantonic® development worldwide: international market.
Country/region Legal status Approval/time of initial launch
USA Dietary supplement September, 2000
The  United Arab Emirates Prescription drug June, 2001
South Korea OTC January, 2002
Cuba Druga July, 2002
Singapore TPMb October, 2002
Mongolia Druga Oct, 2002
Namibia CAMb August, 2003
Kazakhstan Prescription drug January, 2004
South Africa CAMb September, 2005
Vietnam Prescription Drug October, 2005
Russia Prescription drug December, 2005
Ghana CAMb March, 2006
Nigeria CAMb December, 2006
Zambia CAMb January, 2007
Kenya Functional productc March, 2007
India Functional product c March, 2007
Pakistan Prescription drugc April, 2007
Congo Functional productc July, 2007
Botswana CAMc October, 2007
Thailand TMb February, 2008
Hong Kong TCMb March, 2008
Canada OTC July, 2008
Malawi Functional productc December, 2008
Philippines OTC July, 2009
Uganda Functional productc August, 2009
a Drug: there is no clear classiﬁcation between prescription drugs and OTC in some developing countries.
b TPM, Traditional Patent Medicine; CAM, Complementary and Alternative Medicine; TM,  Traditional Medicine; TCM, Traditional Chinese Medicine.
c Functional product: similar to dietary supplement or food supplement.
Table 2
Comparison of herbal regulations in Europe and Asia.
Continents Europe Asia
Country/region EU China Japan South Korea Taiwan
Regulatory Agency National agencies
in each country
(European
Medicines Agency
provides scientiﬁc
opinion to assist
national agencies
in their decision
making process)
State Food and Drug
Administration (SFDA)
The Ministry of
Health, Labor and
Welfare
Korea Food and Drug
Administration (KFDA)
The Committee on Chinese
Medicine and Pharmacy,
Department of Health
Major  legislation or
guidance documents
European Union
Directive
2004/24/EC
SFDA Order 28 – Provision for
Drug Registration;
Supplementary Rules for TCM
Registration
Pharmaceutical
Affairs Law
Pharmaceutical Affairs Act Guideline on examination and
registration of new Chinese
medicines
Category where herbal
products can be
registered (other
than supplements or
health food)
Traditional Herbal
Medicinal
Products,
Prescription or OTC
drugs
Chinese Medicine and Natural
Medicinal Products (9 categories)
Prescription drugs
or OTC drugs
Herbal medicines Chinese medicines
Pharmacopoeia European
Pharmacopoeia
Pharmacopoeia of the PRC Japanese
Pharmacopoeia
Korean Pharmacopoeia,
Korean Herbal
Pharmacopoeia, and
Korean Pharmaceutical
Codex
Chinese Pharmacopoeia of
Chinese Medicine
Mutual recognition Yes (for EU
Member States
only)
No mutual recognition between
Mainland China and its Special
Administrative Regions such as
Hong Kong and Macau
No No No
Uniqueness 30/15 years of
traditional use;
Beneﬁt-risk
methodology
Regulations tailored for TCM;
State secrets may  be granted to
certain variety of TCM for
interests protection; For ancient
classical TCM formula
(documented in or before Qing
dynasty i.e. before AD 1912), the
need of clinical trial safety data
may  be waived; different
categories of Chinese medicine
may  have different requirement
on clinical trials
Over 200 formula
are listed as
“Standards of
Approval for the
Kampo
Formulation”
Preparations with the same
ingredients, dosages, and
efﬁcacy that are included
in the ten traditional
Korean medicinal
references, indicated by
the Ministry of Health and
Welfare Notiﬁcation, do
not need to submit data on
the safety and efﬁcacy of
the preparation.
Formulas listed in
well-established publications
can be used as the formulation
basis. The well-established
publications mentioned in this
Chapter refers to “Yi Zong Jin
Jian”, “Yi Fang Ji Jie”, “Ben Cao
Gang Mu”, “Ben Cao Shi Yi”,
“Ben Cao Bei Yao”, China
Medicine Big Dictionary and
China Pharmacy Big Dictionary.
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Table  3
Comparison of herbal regulations in Eurasia, Australia, North America and South America.
Continents Eurasia Australia North America South America
Country/region Russia Australia Canada US Brazil
Regulatory Agency Ministry of Public Health and
Social Development of Russian
Federation
Ofﬁce of Complentary
Medicines (OCM),
Therapeutic Goods
Administration (TGA)
Natural Health
Products Directorate
(NHPD), Health Canada
Food and Drug
Administration (FDA)
The National
Health Surveillance
Agency (ANVISA)
Major  legislation or
guidance documents
Federal Law No. 61 FZ (dated
12.04.2010) “About circulation
of drugs”
Australian regulatory
guidelines for
complementary
medicines (ARGCM)
Natural Health
Products Regulations
(under Food and Drug
Act)
Federal Food, Drug, and
Cosmetic Act;
Guidance for Industry
Botanical Drug
Products
Resolucao-RDC No.
14, de 31 de Marco
de 2010
(Resolution RDC
No. 14, 31 March
2010)
Category  where herbal
products can be
registered (other
than supplements or
health food)
Herbal medicinal preparations Complementary
Medicine
Natural Health Product Botanical Drug
Products
(food/drug/medical
device/cosmetics)
Herbal Medicines
(prescription and
OTC)
Pharmacopoeia State Pharmacopoeia of
Russian Federation
British Pharmacopoeia Homeopathic
Pharmacopoeia of the
United States, the
Homöopathische
Arzneimittel, the
Pharmacopée franc¸ aise
or the European
Pharmacopoeia
United States
Pharmacopeia (USP)
Brazilian
Pharmacopoeia
(FBras. Farmacopéia
brasileira)
Mutual recognition No Not stated Possible No No
Uniqueness Herbal medicinal preparation
can be classiﬁed into 5
different categories, namely
Medicinal plant materials,
Summarised non-reﬁned or
galenic formulations,
Novo-galenic formulations, 4.
Active pharmaceutical
ingredients (API) and
Combined phytopreparations
Level of evidence in
supporting efﬁcacy and
safety; Early market
access for low-risk
complementary
medicines through
Listed medicine system
(2 tier-system)
Health claim schedules
with reference to US
FDA
Clinical trials in the US
required despite
traditional use history;
Marketing under OTC
Drug Monograph
versus Approved NDA
Herbal medicines
have the same
status as other
medicines; safety &
efﬁcacy must be
demonstrated or
‘traditional use’ (20
years); very
particular
requirements for
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En regulatory affairs, it is prudent to refer to websites
ecause regulations are constantly evolving and being
pdated. Referral to a website is deemed to be best because
t ensures that the reader is taken to the most recent and
p-to-date information. If a particular reference is
rovided, there is the risk that the reader will use
ut-of-date information when planning their regulatory
trategy and ultimately their application.
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